184 related articles for article (PubMed ID: 36644147)
1. Apatinib combined with trastuzumab and albumin-bound paclitaxel for treatment of HER2+ breast cancer with brain metastases resistant to anti-HER2 TKIs: A case report.
Huang J; Chen X; Guo J; Song L; Mu Y; Zhao H; Du C
Oncol Lett; 2023 Feb; 25(2):56. PubMed ID: 36644147
[TBL] [Abstract][Full Text] [Related]
2. The reversal of anti-HER2 resistance in advanced HER2-positive breast cancer using apatinib: two cases reports and literature review.
He L; Shen X; Liu Y; Gao L; Wu J; Yu C; Li G; Wang X; Shao X
Transl Cancer Res; 2022 Nov; 11(11):4206-4217. PubMed ID: 36523304
[TBL] [Abstract][Full Text] [Related]
3. Significant response to apatinib monotherapy in heavily pretreated advanced HER2-positive breast cancer: a case report and literature review.
Danni L; Lingyun Z; Jian W; Hongfei Y; Lu X; Peng Y; Xiujuan Q; Yunpeng L; Yuee T
Cancer Biol Ther; 2020 Jul; 21(7):590-596. PubMed ID: 32233990
[TBL] [Abstract][Full Text] [Related]
4. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases.
Ricciardi GR; Russo A; Franchina T; Ferraro G; Adamo V
Onco Targets Ther; 2015; 8():289-94. PubMed ID: 25678799
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
[TBL] [Abstract][Full Text] [Related]
7. Significant effect of posterior line treatment of HER2 positive advanced gastric cancer: A case report.
Ma X; Xue L; Ou K; Liu X; Chen J; Gao L; Yang L
Heliyon; 2024 Apr; 10(7):e28923. PubMed ID: 38586326
[TBL] [Abstract][Full Text] [Related]
8. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Murthy RK; Loi S; Okines A; Paplomata E; Hamilton E; Hurvitz SA; Lin NU; Borges V; Abramson V; Anders C; Bedard PL; Oliveira M; Jakobsen E; Bachelot T; Shachar SS; Müller V; Braga S; Duhoux FP; Greil R; Cameron D; Carey LA; Curigliano G; Gelmon K; Hortobagyi G; Krop I; Loibl S; Pegram M; Slamon D; Palanca-Wessels MC; Walker L; Feng W; Winer EP
N Engl J Med; 2020 Feb; 382(7):597-609. PubMed ID: 31825569
[TBL] [Abstract][Full Text] [Related]
9. Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases.
Ma X; Li Y; Li L; Gao C; Liu D; Li H; Zhao Z; Zhao B
Ann Med; 2022 Dec; 54(1):3085-3095. PubMed ID: 36331291
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
Yeo W; Luk MY; Soong IS; Yuen TY; Ng TY; Mo FK; Chan K; Wong SY; Tsang J; Leung C; Suen JJ; Ngan RK
Hong Kong Med J; 2018 Feb; 24(1):56-62. PubMed ID: 29326401
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Larsen PB; Kümler I; Nielsen DL
Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.
Pistilli B; Pluard T; Urruticoechea A; Farci D; Kong A; Bachelot T; Chan S; Han HS; Jerusalem G; Urban P; Robinson D; Mouhaër SL; Tomaso ED; Massacesi C; Saura C
Breast Cancer Res Treat; 2018 Apr; 168(2):357-364. PubMed ID: 29198055
[TBL] [Abstract][Full Text] [Related]
13. Remarkable response with pembrolizumab plus albumin-bound paclitaxel in 2 cases of HER2-positive metastatic breast cancer who have failed to multi-anti-HER2 targeted therapy.
Li B; Tao W; Shao-Hua Z; Ze-Rui Q; Fu-Quan J; Fan L; Ze-Fei J
Cancer Biol Ther; 2018 Apr; 19(4):292-295. PubMed ID: 29333945
[TBL] [Abstract][Full Text] [Related]
14. Adding of apatinib and camrelizumab to overcome
Lv H; He Y; Nie C; Du F; Chen X
Front Pharmacol; 2022; 13():1067557. PubMed ID: 36699065
[No Abstract] [Full Text] [Related]
15. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
[TBL] [Abstract][Full Text] [Related]
16. Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report.
Huang LT; Ma JT; Zhang SL; Li XH; Sun L; Jing W; Zhao JZ; Wang YR; Han CB
Front Oncol; 2019; 9():1453. PubMed ID: 31956604
[No Abstract] [Full Text] [Related]
17. A Real-World Multicentre Retrospective Study of Low-Dose Apatinib for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
Zeng T; Sun C; Liang Y; Yang F; Yan X; Bao S; Zhang Y; Huang X; Fu Z; Li W; Yin Y
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077621
[TBL] [Abstract][Full Text] [Related]
18. Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer.
Tanaka S; Iwamoto M; Kimura K; Matsunami N; Morishima H; Yoshidome K; Nomura T; Morimoto T; Yamamoto D; Tsubota Y; Kobayashi T; Uchiyama K
Clin Breast Cancer; 2015 Jun; 15(3):191-6. PubMed ID: 25579459
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
Tevaarwerk AJ; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
[TBL] [Abstract][Full Text] [Related]
20. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
Canonici A; Ivers L; Conlon NT; Pedersen K; Gaynor N; Browne BC; O'Brien NA; Gullo G; Collins DM; O'Donovan N; Crown J
Invest New Drugs; 2019 Jun; 37(3):441-451. PubMed ID: 30062574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
